LUCD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lucid Diagnostics Inc. (LUCD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows potential for growth in the long term, driven by expected Medicare coverage in 2026 and a raised price target by analysts, the company's financial performance remains weak with declining net income, EPS, and gross margin. Additionally, there are no strong technical signals or positive trading trends to support an immediate buy decision.
The technical indicators are mixed. The MACD is slightly positive but contracting, RSI is neutral at 45.32, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 1.35, and resistance is at 1.488. The stock has a 70% chance of gaining 20.81% in the next month, but this is speculative.
The stock has bullish moving averages, and there is a potential for a 20.81% gain in the next month based on candlestick patterns.
The company's financial performance in Q3 2025 shows declining net income (-15.96% YoY), EPS (-60% YoY), and gross margin (-7.31% YoY). There is no recent news or significant trading activity from hedge funds, insiders, or Congress. The RSI is neutral, and there are no strong technical signals for immediate action.
In Q3 2025, revenue increased by 3.33% YoY to $1,211,000. However, net income dropped by 15.96% YoY to -$10,397,000, EPS fell by 60% YoY to -0.1, and gross margin decreased by 7.31% YoY to -48.8.
Analyst Edward Woo from Ascendiant maintains a Buy rating and raised the price target to $8.25 from $8, citing high growth potential and Medicare coverage in 2026 as key drivers for the stock.
